FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2960982763> ?p ?o ?g. }

• W2960982763 abstract "161Tb is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed 177Lu. The therapeutic effect of 161Tb, however, may be enhanced due to the co-emission of a larger number of conversion and Auger electrons as compared to 177Lu. The aim of this study was to produce 161Tb from enriched 160Gd targets in quantity and quality sufficient for first application in patients.No-carrier-added 161Tb was produced by neutron irradiation of enriched 160Gd targets at nuclear research reactors. The 161Tb purification method was developed with the use of cation exchange (Sykam resin) and extraction chromatography (LN3 resin), respectively. The resultant product (161TbCl3) was characterized and the 161Tb purity compared with commercial 177LuCl3. The purity of the final product (161TbCl3) was analyzed by means of γ-ray spectrometry (radionuclidic purity) and radio TLC (radiochemical purity). The radiolabeling yield of 161Tb-DOTA was assessed over a two-week period post processing in order to observe the quality change of the obtained 161Tb towards future clinical application. To understand how the possible drug products (peptides radiolabeled with 161Tb) vary with time, stability of the clinically-applied somatostatin analogue DOTATOC, radiolabeled with 161Tb, was investigated over a 24-h period. The radiolytic stability experiments were compared to those performed with 177Lu-DOTATOC in order to investigate the possible influence of conversion and Auger electrons of 161Tb on peptide disintegration.Irradiations of enriched 160Gd targets yielded 6-20 GBq 161Tb. The final product was obtained at an activity concentration of 11-21 MBq/μL with ≥99% radionuclidic and radiochemical purity. The DOTA chelator was radiolabeled with 161Tb or 177Lu at the molar activity deemed useful for clinical application, even at the two-week time point after end of chemical separation. DOTATOC, radiolabeled with either 161Tb or 177Lu, was stable over 24 h in the presence of a stabilizer.In this study, it was shown that 161Tb can be produced in high activities using different irradiation facilities. The developed method for 161Tb separation from the target material yielded 161TbCl3 in quality suitable for high-specific radiolabeling, relevant for future clinical application." @default.
• W2960982763 created "2019-07-23" @default.
• W2960982763 creator A5006710970 @default.
• W2960982763 creator A5008704894 @default.
• W2960982763 creator A5017255797 @default.
• W2960982763 creator A5027075021 @default.
• W2960982763 creator A5041743198 @default.
• W2960982763 creator A5056614563 @default.
• W2960982763 creator A5057551452 @default.
• W2960982763 creator A5066861861 @default.
• W2960982763 creator A5074602256 @default.
• W2960982763 date "2019-07-10" @default.
• W2960982763 modified "2023-10-12" @default.
• W2960982763 title "Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy" @default.
• W2960982763 cites W1976401545 @default.
• W2960982763 cites W1981002414 @default.
• W2960982763 cites W1993872787 @default.
• W2960982763 cites W2019911597 @default.
• W2960982763 cites W2031586165 @default.
• W2960982763 cites W2032628188 @default.
• W2960982763 cites W2049706787 @default.
• W2960982763 cites W2061365452 @default.
• W2960982763 cites W2076997944 @default.
• W2960982763 cites W2079241416 @default.
• W2960982763 cites W2090631269 @default.
• W2960982763 cites W2108613323 @default.
• W2960982763 cites W2130959358 @default.
• W2960982763 cites W2143006470 @default.
• W2960982763 cites W2145615274 @default.
• W2960982763 cites W2148113725 @default.
• W2960982763 cites W2294365458 @default.
• W2960982763 cites W2416734619 @default.
• W2960982763 cites W2464751836 @default.
• W2960982763 cites W2473078107 @default.
• W2960982763 cites W2554889447 @default.
• W2960982763 cites W2573369749 @default.
• W2960982763 cites W2787486513 @default.
• W2960982763 cites W2802648531 @default.
• W2960982763 cites W2884748155 @default.
• W2960982763 cites W4234933790 @default.
• W2960982763 doi "https://doi.org/10.1186/s41181-019-0063-6" @default.
• W2960982763 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6620226" @default.
• W2960982763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31659528" @default.
• W2960982763 hasPublicationYear "2019" @default.
• W2960982763 type Work @default.
• W2960982763 sameAs 2960982763 @default.
• W2960982763 citedByCount "47" @default.
• W2960982763 countsByYear W29609827632020 @default.
• W2960982763 countsByYear W29609827632021 @default.
• W2960982763 countsByYear W29609827632022 @default.
• W2960982763 countsByYear W29609827632023 @default.
• W2960982763 crossrefType "journal-article" @default.
• W2960982763 hasAuthorship W2960982763A5006710970 @default.
• W2960982763 hasAuthorship W2960982763A5008704894 @default.
• W2960982763 hasAuthorship W2960982763A5017255797 @default.
• W2960982763 hasAuthorship W2960982763A5027075021 @default.
• W2960982763 hasAuthorship W2960982763A5041743198 @default.
• W2960982763 hasAuthorship W2960982763A5056614563 @default.
• W2960982763 hasAuthorship W2960982763A5057551452 @default.
• W2960982763 hasAuthorship W2960982763A5066861861 @default.
• W2960982763 hasAuthorship W2960982763A5074602256 @default.
• W2960982763 hasBestOaLocation W29609827631 @default.
• W2960982763 hasConcept C111337013 @default.
• W2960982763 hasConcept C121332964 @default.
• W2960982763 hasConcept C134121241 @default.
• W2960982763 hasConcept C13965031 @default.
• W2960982763 hasConcept C158973077 @default.
• W2960982763 hasConcept C177322064 @default.
• W2960982763 hasConcept C178790620 @default.
• W2960982763 hasConcept C181199279 @default.
• W2960982763 hasConcept C185544564 @default.
• W2960982763 hasConcept C185592680 @default.
• W2960982763 hasConcept C191897082 @default.
• W2960982763 hasConcept C192562407 @default.
• W2960982763 hasConcept C197404232 @default.
• W2960982763 hasConcept C198684833 @default.
• W2960982763 hasConcept C2779931791 @default.
• W2960982763 hasConcept C2989005 @default.
• W2960982763 hasConcept C2993559085 @default.
• W2960982763 hasConcept C43617362 @default.
• W2960982763 hasConcept C71924100 @default.
• W2960982763 hasConceptScore W2960982763C111337013 @default.
• W2960982763 hasConceptScore W2960982763C121332964 @default.
• W2960982763 hasConceptScore W2960982763C134121241 @default.
• W2960982763 hasConceptScore W2960982763C13965031 @default.
• W2960982763 hasConceptScore W2960982763C158973077 @default.
• W2960982763 hasConceptScore W2960982763C177322064 @default.
• W2960982763 hasConceptScore W2960982763C178790620 @default.
• W2960982763 hasConceptScore W2960982763C181199279 @default.
• W2960982763 hasConceptScore W2960982763C185544564 @default.
• W2960982763 hasConceptScore W2960982763C185592680 @default.
• W2960982763 hasConceptScore W2960982763C191897082 @default.
• W2960982763 hasConceptScore W2960982763C192562407 @default.
• W2960982763 hasConceptScore W2960982763C197404232 @default.
• W2960982763 hasConceptScore W2960982763C198684833 @default.
• W2960982763 hasConceptScore W2960982763C2779931791 @default.
• W2960982763 hasConceptScore W2960982763C2989005 @default.
• W2960982763 hasConceptScore W2960982763C2993559085 @default.
• W2960982763 hasConceptScore W2960982763C43617362 @default.
• W2960982763 hasConceptScore W2960982763C71924100 @default.

• next